========================================
   JAICE Dashboard Startup Script
========================================

Î“Â£Ã  Node.js found

Î“Â£Ã  Project structure verified

Î“Â£Ã  Dependencies verified

â‰¡Æ’ÃœÃ‡ Starting JAICE Dashboard...

Frontend will be available at: http://localhost:5173
Backend API will be available at: http://localhost:3005

Press Ctrl+C to stop both servers
========================================


> jaice-dashboard@0.0.1 start
> concurrently "npm run dev" "cd server && npm start"

(node:35756) [DEP0060] DeprecationWarning: The `util._extend` API is deprecated. Please use Object.assign() instead.
(Use `node --trace-deprecation ...` to show where the warning was created)
[0]
[0] > jaice-dashboard@0.0.1 dev
[0] > vite
[0]
[1]
[1] > jaice-dashboard-server@1.0.0 start
[1] > node server.mjs
[1]
[0]
[0]   VITE v5.4.20  ready in 621 ms
[0]
[0]   âžœ  Local:   http://localhost:5173/
[0]   âžœ  Network: use --host to expose
[1] ðŸš€ JAICE Dashboard Server running on http://localhost:3005
[1] ðŸ“Š Content Analysis API available at http://localhost:3005/api/ca
[1] âœ… OpenAI API key configured - AI generation enabled
[1] ðŸ”— Frontend should connect to: http://localhost:3005
[1] Transcript upload request received
[1] Request body: [Object: null prototype] {
[1]   projectId: 'demo',
[1]   activeSheet: 'Demographics',
[1]   currentData: '{"Demographics":[{"Respondent ID":"","Specialty":"","Date":"","Time (ET)":""}],"INTRODUCTION":[{"Respondent ID":"","Question":""}],"BACKGROUND":[{"Respondent ID":"","Brief Introduction":"","Unique Patient Population":"","Overall SMA Patient Population":"","Number of Patients Managed":"","Age Range":"","Typical Approach to Treating SMA":"","Preferred Treatments":""}],"CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT":[{"Respondent ID":"","Heard of New Formulation or Dosing Options":"","New Treatment Awareness":"","Initial Thoughts on New Treatment":"","Source of Information":"","Level of Interest":"","Patient Benefit":"","Impact on Prescribing":""}],"EVRYSDI TABLET PRODUCT PROFILE REVIEW":[{"Respondent ID":"","Overall Impression":"","Questions About Product":"","Address Gaps or Unmet Needs":"","Most Interesting Information":"","Effectiveness Perception":"","Safety Perception":"","Initial Reaction to Administration Modes":"","Candidates for Evrysdi Tablet":"","Proactive Communication":"","Reasons for Offering Evrysdi Tablet":"","Future Use of Evrysdi":""}],"COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT":[{"Respondent ID":"","Overall Impression of DEVOTE Findings":"","Questions About High Dose Spinraza":"","Address Gaps or Unmet Needs":"","Most InterestingInformation":"","Trial Design Awareness":"","Initial Reaction to Changes":"","Impact on Perceptions":"","Initial Thoughts on Plasma NfL Levels":"","Initial Thoughts on Functional Outcomes":"","Initial Thoughts on Survival Data":"","InitialThoughts on Safety Data":"","Impact Scale Responses":"","Candidates for High Dose Spinraza":"","Proactive Communication":"","Reasons for Offering High Dose Spinraza":"","Future Use of Spinraza":"","Candidates for Zolgensma":"","Proactive Communication for Zolgensma":"","Reasons for Offering Zolgensma":""}],"THANK AND CONCLUDE":[{"Respondent ID":"","Last Comments":""}]}'
[1] }
[1] Request file: {
[1]   fieldname: 'transcript',
[1]   originalname: 'SMA Demand Qual - HCP Interview_5pm.docx',
[1]   encoding: '7bit',
[1]   mimetype: 'application/vnd.openxmlformats-officedocument.wordprocessingml.document',
[1]   destination: './uploads',
[1]   filename: 'transcript_1759182374796.docx',
[1]   path: 'uploads\\transcript_1759182374796.docx',
[1]   size: 51832
[1] }
[1] Processing transcript for project: demo, sheet: Demographics
[1] File details: {
[1]   originalname: 'SMA Demand Qual - HCP Interview_5pm.docx',
[1]   mimetype: 'application/vnd.openxmlformats-officedocument.wordprocessingml.document',
[1]   size: 51832,
[1]   path: 'uploads\\transcript_1759182374796.docx'
[1] }
[1] Processing DOCX file with mammoth...
[1] Successfully extracted 73877 characters from DOCX file
[1] DOCX content preview: SMA Demand Qual
[1]
[1] (Sep 5, 2024 - 5:00pm)
[1]
[1]
[1]
[1] (00:00:04 - 00:00:41)
[1]
[1]     Stacey: Thank you for your time today. I appreciate it. Just to quickly reiterate, our topic today is going to be SMA. I think you ar...
[1] Using current data structure: [
[1]   'Demographics',
[1]   'INTRODUCTION',
[1]   'BACKGROUND',
[1]   'CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT',
[1]   'EVRYSDI TABLET PRODUCT PROFILE REVIEW',
[1]   'COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT',
[1]   'THANK AND CONCLUDE'
[1] ]
[1] Transcript text length: 73877
[1] Transcript preview: SMA Demand Qual
[1]
[1] (Sep 5, 2024 - 5:00pm)
[1]
[1]
[1]
[1] (00:00:04 - 00:00:41)
[1]
[1]     Stacey: Thank you for your time today. I appreciate it. Just to quickly reiterate, our topic today is going to be SMA. I think you ar...
[1] Processing transcript with AI for ALL sheets...
[1] Available sheets: [
[1]   'Demographics',
[1]   'INTRODUCTION',
[1]   'BACKGROUND',
[1]   'CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT',
[1]   'EVRYSDI TABLET PRODUCT PROFILE REVIEW',
[1]   'COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT',
[1]   'THANK AND CONCLUDE'
[1] ]
[1] Discussion guide available: false
[1] Transcript preview (first 500 chars): SMA Demand Qual
[1]
[1] (Sep 5, 2024 - 5:00pm)
[1]
[1]
[1]
[1] (00:00:04 - 00:00:41)
[1]
[1]     Stacey: Thank you for your time today. I appreciate it. Just to quickly reiterate, our topic today is going to be SMA. I think you are anticipating that, and, we have an hour call together. I know we're getting started just a few minutes late, so it's about, seven after. So I'll plan to to finish about seven after six or whatever time it is in your time zone. Alright? And then I oh, sorry. Just it, like, kinda went crazy there fo
[1] Next respondent ID: 1
[1] Skipping demographics - should be manually entered
[1] Processing sheet: INTRODUCTION with columns: [ 'Respondent ID', 'Question' ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Question" in Sheet: "INTRODUCTION"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for INTRODUCTION : {
[1]   'Respondent ID': '1',
[1]   Question: Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processing sheet: BACKGROUND with columns: [
[1]   'Respondent ID',
[1]   'Brief Introduction',
[1]   'Unique Patient Population',
[1]   'Overall SMA Patient Population',
[1]   'Number of Patients Managed',
[1]   'Age Range',
[1]   'Typical Approach to Treating SMA',
[1]   'Preferred Treatments'
[1] ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Brief Introduction" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Unique Patient Population" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Overall SMA Patient Population" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Number of Patients Managed" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Age Range" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Typical Approach to Treating SMA" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Preferred Treatments" in Sheet: "BACKGROUND"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for BACKGROUND : {
[1]   'Respondent ID': '1',
[1]   'Brief Introduction': Promise { <pending> },
[1]   'Unique Patient Population': Promise { <pending> },
[1]   'Overall SMA Patient Population': Promise { <pending> },
[1]   'Number of Patients Managed': Promise { <pending> },
[1]   'Age Range': Promise { <pending> },
[1]   'Typical Approach to Treating SMA': Promise { <pending> },
[1]   'Preferred Treatments': Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processing sheet: CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT with columns: [
[1]   'Respondent ID',
[1]   'Heard of New Formulation or Dosing Options',
[1]   'New Treatment Awareness',
[1]   'Initial Thoughts on New Treatment',
[1]   'Source of Information',
[1]   'Level of Interest',
[1]   'Patient Benefit',
[1]   'Impact on Prescribing'
[1] ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Heard of New Formulation or Dosing Options" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "New Treatment Awareness" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Thoughts on New Treatment" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Source of Information" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Level of Interest" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Patient Benefit" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Impact on Prescribing" in Sheet: "CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT : {
[1]   'Respondent ID': '1',
[1]   'Heard of New Formulation or Dosing Options': Promise { <pending> },
[1]   'New Treatment Awareness': Promise { <pending> },
[1]   'Initial Thoughts on New Treatment': Promise { <pending> },
[1]   'Source of Information': Promise { <pending> },
[1]   'Level of Interest': Promise { <pending> },
[1]   'Patient Benefit': Promise { <pending> },
[1]   'Impact on Prescribing': Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processing sheet: EVRYSDI TABLET PRODUCT PROFILE REVIEW with columns: [
[1]   'Respondent ID',
[1]   'Overall Impression',
[1]   'Questions About Product',
[1]   'Address Gaps or Unmet Needs',
[1]   'Most Interesting Information',
[1]   'Effectiveness Perception',
[1]   'Safety Perception',
[1]   'Initial Reaction to Administration Modes',
[1]   'Candidates for Evrysdi Tablet',
[1]   'Proactive Communication',
[1]   'Reasons for Offering Evrysdi Tablet',
[1]   'Future Use of Evrysdi'
[1] ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Overall Impression" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Questions About Product" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Address Gaps or Unmet Needs" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Most Interesting Information" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Effectiveness Perception" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Safety Perception" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Reaction to Administration Modes" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Candidates for Evrysdi Tablet" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Proactive Communication" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Reasons for Offering Evrysdi Tablet" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Future Use of Evrysdi" in Sheet: "EVRYSDI TABLET PRODUCT PROFILE REVIEW"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for EVRYSDI TABLET PRODUCT PROFILE REVIEW : {
[1]   'Respondent ID': '1',
[1]   'Overall Impression': Promise { <pending> },
[1]   'Questions About Product': Promise { <pending> },
[1]   'Address Gaps or Unmet Needs': Promise { <pending> },
[1]   'Most Interesting Information': Promise { <pending> },
[1]   'Effectiveness Perception': Promise { <pending> },
[1]   'Safety Perception': Promise { <pending> },
[1]   'Initial Reaction to Administration Modes': Promise { <pending> },
[1]   'Candidates for Evrysdi Tablet': Promise { <pending> },
[1]   'Proactive Communication': Promise { <pending> },
[1]   'Reasons for Offering Evrysdi Tablet': Promise { <pending> },
[1]   'Future Use of Evrysdi': Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processing sheet: COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT with columns: [
[1]   'Respondent ID',
[1]   'Overall Impression of DEVOTE Findings',
[1]   'Questions About High Dose Spinraza',
[1]   'Address Gaps or Unmet Needs',
[1]   'Most Interesting Information',
[1]   'Trial Design Awareness',
[1]   'Initial Reaction to Changes',
[1]   'Impact on Perceptions',
[1]   'Initial Thoughts on Plasma NfL Levels',
[1]   'Initial Thoughts on Functional Outcomes',
[1]   'Initial Thoughts on Survival Data',
[1]   'Initial Thoughts on Safety Data',
[1]   'Impact Scale Responses',
[1]   'Candidates for High Dose Spinraza',
[1]   'Proactive Communication',
[1]   'Reasons for Offering High Dose Spinraza',
[1]   'Future Use of Spinraza',
[1]   'Candidates for Zolgensma',
[1]   'Proactive Communication for Zolgensma',
[1]   'Reasons for Offering Zolgensma'
[1] ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Overall Impression of DEVOTE Findings" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Questions About High Dose Spinraza" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Address Gaps or Unmet Needs" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Most Interesting Information" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Trial Design Awareness" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Reaction to Changes" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Impact on Perceptions" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Thoughts on Plasma NfL Levels" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Thoughts on Functional Outcomes" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Thoughts on Survival Data" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Initial Thoughts on Safety Data" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Impact Scale Responses" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Candidates for High Dose Spinraza" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Proactive Communication" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Reasons for Offering High Dose Spinraza" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Future Use of Spinraza" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Candidates for Zolgensma" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Proactive Communication for Zolgensma" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Reasons for Offering Zolgensma" in Sheet: "COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT : {
[1]   'Respondent ID': '1',
[1]   'Overall Impression of DEVOTE Findings': Promise { <pending> },
[1]   'Questions About High Dose Spinraza': Promise { <pending> },
[1]   'Address Gaps or Unmet Needs': Promise { <pending> },
[1]   'Most Interesting Information': Promise { <pending> },
[1]   'Trial Design Awareness': Promise { <pending> },
[1]   'Initial Reaction to Changes': Promise { <pending> },
[1]   'Impact on Perceptions': Promise { <pending> },
[1]   'Initial Thoughts on Plasma NfL Levels': Promise { <pending> },
[1]   'Initial Thoughts on Functional Outcomes': Promise { <pending> },
[1]   'Initial Thoughts on Survival Data': Promise { <pending> },
[1]   'Initial Thoughts on Safety Data': Promise { <pending> },
[1]   'Impact Scale Responses': Promise { <pending> },
[1]   'Candidates for High Dose Spinraza': Promise { <pending> },
[1]   'Proactive Communication': Promise { <pending> },
[1]   'Reasons for Offering High Dose Spinraza': Promise { <pending> },
[1]   'Future Use of Spinraza': Promise { <pending> },
[1]   'Candidates for Zolgensma': Promise { <pending> },
[1]   'Proactive Communication for Zolgensma': Promise { <pending> },
[1]   'Reasons for Offering Zolgensma': Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processing sheet: THANK AND CONCLUDE with columns: [ 'Respondent ID', 'Last Comments' ]
[1]
[1] === AI TRANSCRIPT ANALYSIS ===
[1] Column: "Last Comments" in Sheet: "THANK AND CONCLUDE"
[1] Transcript length: 73877 characters
[1] Moderator comments found: 20
[1] Respondent responses found: 1011
[1] Parsed transcript - Respondent responses: 1011
[1] Respondent text length: 60843
[1] Generated respondent data for THANK AND CONCLUDE : {
[1]   'Respondent ID': '1',
[1]   'Last Comments': Promise { <pending> },
[1]   Date: '09/29/2025',
[1]   'Time (ET)': '05:46 PM'
[1] }
[1] Processed sheets: [
[1]   'INTRODUCTION',
[1]   'BACKGROUND',
[1]   'CURRENT AWARENESS AND PERCEPTIONS OF TREATMENTS IN DEVELOPMENT',
[1]   'EVRYSDI TABLET PRODUCT PROFILE REVIEW',
[1]   'COMPETITIVE COMPARISON TO OTHER TREATMENTS IN DEVELOPMENT',
[1]   'THANK AND CONCLUDE'
[1] ]
[1] Total sheets updated: 6
[1] Uploaded file cleaned up successfully
[1] Transcript processing completed successfully
[1] Generated analysis: Heard of New Formulation or Dosing Options: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent believes this would impact prescribing by do you prefer that they start on spinraza, and and then, you know, perhaps make a change down...
[1] Generated analysis: Age range: (00:02:38 - 00:02:45) (00:02:46 - 00:03:41) Nivedita: So I run a big neuromaster clinic, and the clinic was kind of designed from scratch a...
[1] Generated analysis: The respondent's overall impression is that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: The respondent identified key benefits including your next thing is that they liked it because there's a lot more evidence and data with the younger p...
[1] Generated analysis: Candidates for Zolgensma: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: The respondent showed high interest and enthusiasm, actively engaging with the topic...
[1] Generated analysis: Effectiveness Perception: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: Future Use of Evrysdi: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Source of Information: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Proactive Communication: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Proactive Communication for Zolgensma: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 -00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: Reasons for Offering Evrysdi Tablet: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent believes this would impact prescribing by do you prefer that they start on spinraza, and and then, you know, perhaps make a change down...
[1] Generated analysis: The respondent's overall impression is that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: Questions About High Dose Spinraza: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Candidates for High Dose Spinraza: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent showed high interest and enthusiasm, actively engaging with the topic...
[1] Generated analysis: Future Use of Spinraza: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Brief Introduction: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Safety Perception: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita:No...
[1] Generated analysis: The respondent's overall impression is that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: Reasons for Offering High Dose Spinraza: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41- 00:00:44) Nivedita: No...
[1] Generated analysis: Questions About Product: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's preferences include so, we'll do our best to try to avoid those things today  so we have a lot of accolades, peripheral nerve center ...
[1] Generated analysis: Address Gaps or Unmet Needs: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44)Nivedita: No...
[1] Generated analysis: Address Gaps or Unmet Needs: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44)Nivedita: No...
[1] Generated analysis: Candidates for Evrysdi Tablet: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's initial thoughts were that and, i work for an independent research group, so we have no vested interest in the comments that you shar...
[1] Generated analysis: The respondent manages approximately 2024 patients in their practice...
[1] Generated analysis: Reasons for Offering Zolgensma: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent's approach to treating SMA involves (00:04:32 - 00:04:32) (00:04:32 - 00:04:32) (00:04:32 - 00:04:32) (00:04:32 - 00:04:41) nivedita: s...
[1] Generated analysis: The respondent manages approximately 2024 patients in their practice...
[1] Generated analysis: Question: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent showed high interest and enthusiasm, actively engaging with the topic...
[1] Generated analysis: New Treatment Awareness: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Last Comments: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Trial Design Awareness: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: Proactive Communication: (Sep 5, 2024 - 5:00pm) (00:00:04 - 00:00:41) (00:00:41 - 00:00:44) Nivedita: No...
[1] Generated analysis: The respondent showed high interest and enthusiasm, actively engaging with the topic...
[1] Generated analysis: The respondent believes this would impact prescribing by do you prefer that they start on spinraza, and and then, you know, perhaps make a change down...
